This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effects of Anthocyans on Cardiovascular and Sympathetic Function

This study has been completed.
Information provided by:
Oslo University Hospital Identifier:
First received: March 5, 2008
Last updated: July 3, 2011
Last verified: February 2010
Anthocyans modify cardiovascular and sympathetic function

Condition Intervention
Hypertension Dietary Supplement: Anthocyans Other: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effects of Anthocyans on Cardiovascular and Sympathetic Function

Further study details as provided by Oslo University Hospital:

Primary Outcome Measures:
  • Systolic bloodpressure and heartrate

Enrollment: 27
Study Start Date: March 2008
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A
Dietary Supplement: Anthocyans
Dietary Supplement: Anthocyans
Placebo Comparator: B
no effective agent
Dietary Supplement: Anthocyans
Other: placebo


Ages Eligible for Study:   35 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ages 35 to 50 years old
  • Males
  • Hypertension
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00634387

Cardiovascular and Renal Research Center, Ulleval University Hospital
Oslo, Norway, 0407
Sponsors and Collaborators
Ullevaal University Hospital
  More Information

Responsible Party: Morten Rostrup MD PhD, Ullevaal University Hospital Identifier: NCT00634387     History of Changes
Other Study ID Numbers: AC2008
Study First Received: March 5, 2008
Last Updated: July 3, 2011 processed this record on September 21, 2017